PATENT PROTECTED HYDROGEL
Our platform technology consists of mainly two materials which have the following properties:
Inverse Thermal Gelling
Our hydrogel provides a sustained therapeutic release which out-competes other available technologies.
AmacaThera is a Toronto-based biotechnology company focused on developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications.
Based on the research of world-renowned biomaterials scientist, Dr. Molly Shoichet, AmacaThera is commercializing combination products at the interface of biomaterials and pharmaceuticals.
We have developed a platform technology which addresses the critical problem of sustaining therapeutic delivery of pharmacological agents for multiple disease areas.
Currently, we have developed a combination product for post-operative pain, which is our company's lead project.
Improving the lives of patients by providing sustained therapeutic release.
Meet The Team
ACADEMIC RESEARCH PAPERS
Papers published on our technology alone
THIRD PARTY VALIDATION
Papers published by independent groups
AMOUNT OF MONEY RAISED